CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 89 enrolled
Drug / intervention
Low dose of VIS410 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03040141
NCT03040141Phase 2Completed

Phase 2b, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of IV VIS410 in Addition to Oseltamivir Compared With Oseltamivir Alone in Hospitalized Adults With Influenza A Infection Requiring Oxygen Support

Visterra, Inc.·interventional·Posted Feb 2, 2017·Updated Dec 28, 2022

In Brief

A Phase 2 clinical trial evaluating Low dose of VIS410, High dose of VIS410, and 1 other intervention for Influenza A. Completed, enrolled 89 participants across 114 sites in 20 countries.

Detailed Summary

This study is to compare the efficacy and safety of VIS410 in combination with oseltamivir vs oseltamivir alone in severely ill subjects with influenza A infection requiring oxygen support.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza A
CountriesAustralia, Belarus, Belgium, Bulgaria, Canada, Estonia, France, Georgia, Latvia, Malaysia, New Zealand, Russia, Serbia, Singapore, South Africa, Spain, Thailand, Turkey (Türkiye), Ukraine, United States
Collaborators--

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedFeb 2, 2017
Enrollment StartJan 3, 2018
Primary CompletionNov 22, 2018
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 9.4 years ago

Interventions

Low dose of VIS410drug

Single intravenous infusion of fixed low dose of VIS410 in addition to oseltamivir

High dose of VIS410drug

Single intravenous infusion of fixed high dose of VIS410 in addition to oseltamivir

Placebodrug

Single intravenous infusion of placebo in addition to oseltamivir